Skip to main content

Table 3 Short-term clinical outcomes of pancreatitis by treatment for immune checkpoint inhibitor-induced pancreatic injury

From: Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury

Outcome Steroids, no. (%) Intravenous fluids, no. (%)
Steroids, n = 31 No steroids, n = 51 P Intravenous fluids, n = 32 No intravenous fluids, n = 50 P
Mean time from peak lipase value to improvement to grade 1a (standard deviation) 55 days (11) 48 days (7) 0.711 55 days (51) 52 days (49) 0.850
Mean duration of symptomsb (standard deviation) 5 days (3) 4 days (2) 0.824 4 days (3) 5 days (3) 0.650
Pseudocyst 1 (3) 2 (4) 1.000 3 (9) 0 (0) 0.056
Hospitalization 6 (19) 9 (18) 1.000 14 (44) 1 (2) <0.001
Mean duration of hospitalization (standard deviation) 4 days (3) 5 days (2) 0.762 5 days (3) 1 day (-) 0.166
Intravenous fluids 14 (45) 18 (35) 0.484 - - -
Steroids - - - 14 (44) 17 (34) 0.484
Immune checkpoint inhibitor therapy interrupted 18 (58) 29 (57) 1.000 22 (69) 25 (50) 0.113
  1. aImprovement was defined as return of lipase value to grade 1.
  2. bDuration of symptoms was measured for 35 patients with symptoms